Partial
Not Aligned
Patient Risk:
High
Summary
The response aligns with several labeling items (indications, subcutaneous every-4-weeks regimen, adult self/caregiver administration, and core psoriasis efficacy endpoints), but contains multiple label-unsupported generalized claims (side effects, cost/coverage, “not a cure”), major dosing-strength misinformation (50–200 mg), and long-duration quality-of-life/sustained claims that are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Cosentyx is a biologic medication.
Label describes secukinumab as a human IgG1 monoclonal antibody (12.1); provided text does not explicitly use the term 'biologic,' so wording is only partially matched.
Cosentyx is used to treat psoriasis.
Indicated for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older (1.1).
Cosentyx is used to treat psoriatic arthritis.
Indicated for active psoriatic arthritis in adults and pediatric patients 2 years and older (1.2).
Cosentyx is used to treat ankylosing spondylitis.
Indicated for active ankylosing spondylitis in adults and pediatric patients 12 years and older (1.3).
Cosentyx is administered through subcutaneous injections.
Subcutaneous use and injection technique described (2.2) and trials described as subcutaneous COSENTYX (14.1).
Cosentyx is typically taken every 4 weeks.
Adults with PsO: every 4 weeks thereafter (2.3); PsA/AS regimens also describe every 4 weeks (2.4, 2.6).
Cosentyx may be used in combination with other medications in some cases.
For PsA, COSENTYX may be administered with or without methotrexate (2.4).
Some patients experienced complete clearance of psoriasis symptoms.
Treatment success defined as IGA 'clear' or 'almost clear' (IGA 0 = clear) (14.1).
Studies demonstrated Cosentyx can achieve significant improvements in Psoriasis Area and Severity Index (PASI) scores.
Trials use PASI-related endpoints (e.g., PASI 75/90 responses) (14.1).
Cosentyx can be administered at home or in a doctor's office.
Label supports adult self-administration or caregiver injection after proper training; no explicit 'doctor’s office' wording in provided sections (2.2).
Combination therapy with Cosentyx and other medications can lead to improved outcomes and reduced symptoms.
Not fully supported as stated; however, label reports responses were similar regardless of concomitant methotrexate in PsA1 (14.3).
Unsupported Statements
Cosentyx was approved in 2015.
No approval-year information is present in the provided label sections.
Early studies showed Cosentyx was effective in reducing symptoms.
The provided sections include trial results but do not support the generalized 'early studies' phrasing or specific timeline.
Early studies showed Cosentyx improved quality of life.
Quality-of-life is mentioned for AS (ASQoL at Week 16), but the generalized 'early studies' and broad linkage to early findings/overall psoriasis are not supported in the provided excerpts.
Cosentyx has been shown to be highly effective in reducing psoriasis symptoms such as redness, scaling, and itching in the short term.
Label supports improvements in itching/pain/scaling and that PASI/IGA reflect erythema and scaling, but does not explicitly state 'highly effective' nor 'short term' as phrased.
Research has shown Cosentyx can continue to improve quality of life over time.
Quality-of-life improvement over time is not supported by the provided psoriasis sections.
A study found that patients who received Cosentyx for up to 5 years experienced sustained improvements in psoriasis symptoms.
Provided sections describe follow-up up to 52 weeks for PsO trials; the provided material does not support 'up to 5 years' for psoriasis.
A study found that patients who received Cosentyx for up to 5 years experienced sustained improvements in quality of life.
No provided label support for up to 5 years quality-of-life for psoriasis.
A survey by the National Psoriasis Foundation found that 9 out of 10 patients who took Cosentyx reported improved symptoms.
No survey/NPF content is present in the provided label sections.
A survey by the National Psoriasis Foundation found that 9 out of 10 patients who took Cosentyx reported improved quality of life.
No survey/NPF content is present in the provided label sections.
Common side effects of Cosentyx include injection site reactions.
Injection site reactions are not listed among adverse reactions in the provided sections.
Common side effects of Cosentyx include upper respiratory infections.
The provided sections do not list upper respiratory infections as common side effects.
Common side effects of Cosentyx include headaches.
Headaches are not listed as common adverse reactions in the provided sections.
The most common side effects of Cosentyx are mild and temporary.
No provided label text gives frequency/severity characterization for 'most common' side effects.
Most patients can continue to take Cosentyx without significant issues.
No label statement provided in the supplied sections with this meaning.
Cosentyx comes in dosages ranging from 50 mg to 200 mg.
Provided label sections describe 75 mg, 150 mg, and 300 mg dosing regimens; 50 mg and 200 mg are not supported by the provided dosing-strength information.
Cosentyx is costly.
No pricing/cost information is present in the provided label sections.
Prices for Cosentyx range from $3,000 to $6,000 per month.
No pricing information is present in the provided label sections.
Many insurance plans and government programs cover Cosentyx.
No coverage information is present in the provided label sections.
Patient assistance programs may be available for those who are uninsured or underinsured.
No patient assistance information is present in the provided label sections.
Cosentyx has been shown to be highly effective in reducing symptoms and improving quality of life for patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
The provided label excerpts support efficacy, but do not support 'highly effective' phrasing across all indications nor quality-of-life improvement across all three indications as stated.
Cosentyx is generally safe and well-tolerated.
No generalized safety/tolerability summary statement is present in the provided label sections.
Most side effects of Cosentyx are mild and temporary.
No provided label text supports this severity characterization.
Cosentyx is not a cure for psoriasis.
No label statement is provided addressing 'not a cure.'
Cosentyx is not a cure for psoriasis, but it can significantly reduce symptoms and improve quality of life.
Symptom reduction is supported via PASI/IGA outcomes, but 'not a cure' and psoriasis quality-of-life improvement as stated are not supported by the provided excerpts.
Many insurance plans and government programs cover Cosentyx.
No coverage information is present in the provided label sections.
Patient assistance programs may be available for those who are uninsured or underinsured.
No patient assistance information is present in the provided label sections.
Research has shown that Cosentyx can continue to provide significant improvements in symptoms and quality of life over time.
Symptom maintenance is supported for psoriasis (e.g., up to Week 52), but quality-of-life over time is not supported for psoriasis in the provided excerpts.
Some patients may experience sustained benefits for up to 5 years.
Provided excerpts do not support psoriasis sustained benefits up to 5 years.
Contradictions
High
AI Statement
Cosentyx comes in dosages ranging from 50 mg to 200 mg.
Label Reference
Dose strengths described in provided label excerpts for subcutaneous regimens are 75 mg, 150 mg, and 300 mg (2.3, 2.4, 2.6).
Important Omissions
Key safety warnings/precautions content (e.g., infections, hypersensitivity, inflammatory bowel disease, eczematous eruptions) and that they are discussed in labeling sections.
Importance:
Moderate
Specific administration constraints not mentioned in the response, including that pediatric patients should not self-administer and that IV use is only in a healthcare setting/adults (as applicable).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
A label-unsupported dosing-strength range (50–200 mg) could create dosing errors; multiple other claims (side effects frequency/severity, long-duration benefit, cure statements) are not label-supported but are less directly dosing-related.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contains a high-severity, label-inconsistent dosing-strength claim (50–200 mg) not supported by the provided label excerpts.
Suggested Improvement
Remove or correct the strength/dose range to match provided label dosing strengths (75 mg, 150 mg, 300 mg) and restrict efficacy/safety/side-effect/cost/coverage statements to what is explicitly supported in the available label text.